eXstent



January 2026

Introduction

- Exstent is a mature, UK-based company, that designs, manufactures and commercialises the ExoVasc ® implant for support of the great vessels
- The ExoVasc® implant provides custom-made vascular support for patients with aortic root dilatation and patients undergoing the Ross procedure
- The ExoVasc® implant effectively prevents dilation and dissection of the treated vessel
- Over 1,500 patients treated to date (UK, EU, Australia) with outstanding clinical results
- Robust portfolio of clinical evidence with 80+ peer-reviewed publications and support from NICE guidelines
- Geographical expansion plans include N America, S America, major EU countries and SE Asia
- FDA: HUD granted and modular HDE application underway
- Company is profitable with double digit revenue growth and margins > 85%
- TAM $180M

ExoVasc® Implant Use

No competitive technology for external support of the great vessels.

Dilation of ascending aorta (Marfan, BAV, Idiopathic)

- TAM $150M

Dilation of pulmonary allograft – Ross

- TAM $30M

Concomitant with mitral valve repair in Marfan

Aortic valve function recovery



Dilatation of the Ascending Aorta – Precursor to Dissection

Three surgical approaches:

1. Total Root Replacement – the Bentall operation
2. Valve Sparing Root Replacement – The Yacoub/David operation
3. Personalised External Aortic Root Support – PEARS using the ExoVasc® implant

Play video

eXstent

Dilatation of the Ascending Aorta – Precursor to Dissection

Current surgical procedures replace the aorta – ExoVasc® preserves it.

- Cardiopulmonary bypass is required.
- Total root replacement with an artificial valve needs lifelong anticoagulation with a 0.7% annual thromboembolic risk.
- Valve-sparing root replacement has a 1.3% annual risk of aortic regurgitation requiring reoperation.
- Up to 20% of patients with connective tissue disorders need secondary intervention.
- There is a clear need for a durable, patient-specific solution that supports the native vessel and preserves natural valve function.



Burgstaller et al EJCTS 2018; 54:411

eXstent

Dilatation of the Ascending Aorta – Precursor to Dissection

- The ExoVasc® implant is a patient-specific external support fitted around the great vessels to reinforce the vessel wall and prevent dilation and dissection.
- Custom-made external support fits each patient
- Preserves native tissue and valve function
- Prevents dilation and reduces reoperation risk
- Compatible with open or hybrid surgery
- With more than two decades of data, Exstent offers the implant proven to reinforce natural tissue and preserve valve function



eXstent

Aortic Surgical Options

	Total Root Replacement (TRR)	**Valve-Sparing Root Replacement** (VSRR)	**Personalised External Root Support** (PEARS)
Operation time (hours)	3 - 6	4 - 7	**2 - 3**
Cardio-Pulmonary Bypass required	**Yes**	**Yes**	**Optional** (CPB in ~20% of cases)
Total body cooling used	**Yes**	**Yes**	**No**
Anticoagulation required for life	**Yes**	No	**No**
Re-operation rate (% per year)	0.3	**1.3**	**→ 0**
Threshold aortic diameter (mm)	45-55	45-55	**40**

Burgstaller et al EJCTS 2018; 54:411
Van Hoof et al Heart 2021:0: 1

eXstent

ExoVasc® Implant and the Ross Procedure

- Replacement of diseased aortic valve with pulmonary valve autograft
- Pulmonary trunk replaced with allograft
- Neo-aorta autograft may dilate in up to 40% of patients over 20y and require re-operation
- ExoVasc® implant can be used at index operation to prevent dilation



Precision Engineering Meets Personalised Care



Cross-sectional imaging
3D printing
of a "former"

Textile mesh on
"former" Shaped
and packaged



ExoVasc® implant
placed during
the PEARS
procedure

eXstent

Clinical Experience with ExoVasc®

Histology demonstrated incorporation of implant into the aortic adventitia and recovery of medial structure

Peri-operative mortality
2 patients (0.13%)

>1,500
Patients treated with ExoVasc® implant

(80% aortic indication, 20% pulmonary autograft)

55
Patients
>10y post-procedure

80+
peer reviewed publications

385
Patients
>5y post-procedure

No patients have reported ongoing **aortic dilatation**

ExoVasc® implant Registry in progress

eXstent

Regulatory Framework

FDA 2016 HUD designation granted for: "Surgical management of aneurysms (dilation) of the aortic root and ascending aorta"



UK:

- Registered as a custom-made device with MHRA
- Use supported by NICE

EU:

- Registered on EUDAMED as a custom-made device
- Conformity Assessment complete against EU MDR 2017/745 with BSI

USA:

- HUD designation granted
- Modular HDE underway
- Predicting approval 2027

AUS:

- Custom-Made Medical Device, currently exempt from ARTG Registration
- Transition required to Patient Matched Device.
- Deadline for inclusion in ARTG, 01 Jul 2029. Submission planned to TGA, H1 2027.

eXstent

Manufacturing

- Manufacturing in Tewkesbury, UK
- 15 employees
- Fully operational clean room, class 7,6,5
- ISO13485:2016, MDSAP, ANVISA GMP,
  EU-MDR Quality certification
- Manufacturing can be scaled to produce 3000 ExoVasc® implants per annum in current premises (493 implants sold in 2025)
- IP – proprietary manufacturing processes

Strong Revenue Growth



- Strong revenue growth from 2021
- 90% revenue from UK, Czechia, Australia, Netherlands, Austria
- Expansion plans include N. America, S. America, SE Asia and major EU countries
- Margin > 85%
- EBITDA positive

Summary

- Exstent is a growth company ready to scale and enter US market
- Manufacturing, regulatory and clinical risks have been retired
- Clinical efficacy is proven, and long-term clinical results are excellent
- Next phase of company evolution will be to explore strategic partnerships to accelerate growth and profitability